Ocata Therapeutics Inc fka OCAT

[AyeEye]

The preclinical trials were the reason for the agreement with Allele; and OCAT anticipates adding more IP.

"...definitive agreement with Allele Biotechnology & Pharmaceuticals, Inc. of San Diego, CA (“Allele”) to access Allele’s proprietary technology for generating human induced pluripotent stem cells (“iPSCs”)."

Ocata is not standing still with SMD and AMD, but is continuing to work on the future pipeline.

Delays for phase II are strategic in order to have clear goals with regulators, so that if results are the same as the Lancet study, then a path to production (SMD) would be able to be expedited.

Aye